Waaree Energies went public in October 2024 and quickly became one of the most discussed IPOs of the year. India's largest solar module manufacturer — with a 12 GW module capacity and a growing cell manufacturing base — Waaree sits at the exact intersection of two powerful themes: India's domestic renewable energy push and the global supply chain diversification away from China.
The Business Model: Modules, Cells, and EPC
Waaree operates across three segments. Module manufacturing is the core — it takes solar cells and assembles them into panels sold to utility-scale developers, rooftop installers, and international customers. Cell manufacturing (4 GW capacity at Chikhli, Gujarat) is the strategically important segment — cells are the active photovoltaic component and have significantly higher margins than assembly. EPC (engineering, procurement, construction) is the smallest segment but provides long-term servicing revenue.
The US IRA Tailwind
The US Inflation Reduction Act provides significant manufacturing incentives for solar equipment made outside China. Waaree has signed a contract to supply modules to a US-based entity from its Texas manufacturing facility. This is transformative — US solar module prices are 30-40% higher than Indian domestic prices due to tariff structures. A meaningful US revenue mix would structurally re-rate Waaree's blended realisation and margin profile.
The Polysilicon Risk
India imports virtually all its polysilicon — the primary raw material for solar cells — from China. This creates two risks: currency exposure and geopolitical supply risk. Any disruption to Chinese polysilicon exports (as happened briefly in 2022) would squeeze cell manufacturers globally. Waaree partially hedges this through long-term supply agreements, but there is no domestic polysilicon production of scale in India, making this a systemic sector risk rather than a company-specific one.
- Module capacity: 12 GW (largest in India)
- Cell capacity: 4 GW (Chikhli, Gujarat)
- Order book: ₹16,000 crore+ (FY25)
- Revenue FY24: ₹11,632 crore (+69% YoY)
- EBITDA margin: ~11-12% (module-heavy mix)
🔍 BBS Insight
Waaree's investment case hinges on two transitions: module-to-cell mix improvement (boosts margins by ~5-6%) and domestic-to-US revenue mix (boosts realisation by 30-40%). Both are happening simultaneously. The risk is that the stock is already pricing significant execution optimism. Read the quarterly results with one key metric in focus: cell manufacturing utilisation rate. If that number is rising consistently, the margin expansion story is on track.